720 related articles for article (PubMed ID: 24884509)
41. Expression and Clinical Role of Cdc5L as a Novel Cell Cycle Protein in Hepatocellular Carcinoma.
Qiu H; Zhang X; Ni W; Shi W; Fan H; Xu J; Chen Y; Ni R; Tao T
Dig Dis Sci; 2016 Mar; 61(3):795-805. PubMed ID: 26553251
[TBL] [Abstract][Full Text] [Related]
42. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4.
Li J; Guo Y; Liang X; Sun M; Wang G; De W; Wu W
J Cancer Res Clin Oncol; 2012 May; 138(5):763-74. PubMed ID: 22270966
[TBL] [Abstract][Full Text] [Related]
43. E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination.
Zhu H; Wang X; Zhou X; Lu S; Gu G; Liu C
Lab Invest; 2022 Nov; 102(11):1203-1213. PubMed ID: 35840806
[TBL] [Abstract][Full Text] [Related]
44. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway.
Yang J; Zhang X; Liu L; Yang X; Qian Q; Du B
Life Sci; 2021 Jan; 264():118711. PubMed ID: 33186566
[TBL] [Abstract][Full Text] [Related]
45. Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Dai XY; Zhuang LH; Wang DD; Zhou TY; Chang LL; Gai RH; Zhu DF; Yang B; Zhu H; He QJ
Oncotarget; 2016 Feb; 7(6):6933-47. PubMed ID: 26771844
[TBL] [Abstract][Full Text] [Related]
46. The RNA-binding protein Sam68 regulates tumor cell viability and hepatic carcinogenesis by inhibiting the transcriptional activity of FOXOs.
Zhang T; Wan C; Shi W; Xu J; Fan H; Zhang S; Lin Z; Ni R; Zhang X
J Mol Histol; 2015 Dec; 46(6):485-97. PubMed ID: 26438629
[TBL] [Abstract][Full Text] [Related]
47. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway.
Fan Y; Du Z; Ding Q; Zhang J; Op Den Winkel M; Gerbes AL; Liu M; Steib CJ
Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33846777
[TBL] [Abstract][Full Text] [Related]
48. FBXW10 promotes hepatocarcinogenesis in male patients and mice.
Luo YD; Zhang J; Fang L; Zhu YY; You YM; Zhang CC; Zheng P; Zhang LD; Yin LY; Xia F; Bie P; Xie CM
Carcinogenesis; 2020 Jul; 41(5):689-698. PubMed ID: 31400758
[TBL] [Abstract][Full Text] [Related]
49. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation.
Li H; Wang S; Wang G; Zhang Z; Wu X; Zhang T; Fu B; Chen G
Dig Surg; 2014; 31(6):468-78. PubMed ID: 25632982
[TBL] [Abstract][Full Text] [Related]
50. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation.
Xi Z; Yao M; Li Y; Xie C; Holst J; Liu T; Cai S; Lao Y; Tan H; Xu HX; Dong Q
Cell Death Dis; 2016 Jun; 7(6):e2252. PubMed ID: 27253416
[TBL] [Abstract][Full Text] [Related]
51. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
52. The oncoprotein HBXIP up-regulates YAP through activation of transcription factor c-Myb to promote growth of liver cancer.
Wang Y; Fang R; Cui M; Zhang W; Bai X; Wang H; Liu B; Zhang X; Ye L
Cancer Lett; 2017 Jan; 385():234-242. PubMed ID: 27765671
[TBL] [Abstract][Full Text] [Related]
53. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
54. FBXL6 governs c-MYC to promote hepatocellular carcinoma through ubiquitination and stabilization of HSP90AA1.
Shi W; Feng L; Dong S; Ning Z; Hua Y; Liu L; Chen Z; Meng Z
Cell Commun Signal; 2020 Jun; 18(1):100. PubMed ID: 32576198
[TBL] [Abstract][Full Text] [Related]
55. The RNF214-TEAD-YAP signaling axis promotes hepatocellular carcinoma progression via TEAD ubiquitylation.
Lin M; Zheng X; Yan J; Huang F; Chen Y; Ding R; Wan J; Zhang L; Wang C; Pan J; Cao X; Fu K; Lou Y; Feng XH; Ji J; Zhao B; Lan F; Shen L; He X; Qiu Y; Jin J
Nat Commun; 2024 Jun; 15(1):4995. PubMed ID: 38862474
[TBL] [Abstract][Full Text] [Related]
56. FBXW7 suppresses epithelial-mesenchymal transition and chemo-resistance of non-small-cell lung cancer cells by targeting snai1 for ubiquitin-dependent degradation.
Xiao G; Li Y; Wang M; Li X; Qin S; Sun X; Liang R; Zhang B; Du N; Xu C; Ren H; Liu D
Cell Prolif; 2018 Oct; 51(5):e12473. PubMed ID: 30094882
[TBL] [Abstract][Full Text] [Related]
57. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
[TBL] [Abstract][Full Text] [Related]
58. CIZ1 interacts with YAP and activates its transcriptional activity in hepatocellular carcinoma cells.
Lei L; Wu J; Gu D; Liu H; Wang S
Tumour Biol; 2016 Aug; 37(8):11073-9. PubMed ID: 26906552
[TBL] [Abstract][Full Text] [Related]
59. PSMD9 promotes the malignant progression of hepatocellular carcinoma by interacting with c-Cbl to activate EGFR signaling and recycling.
Su Y; Meng L; Ge C; Liu Y; Zhang C; Yang Y; Tian W; Tian H
J Exp Clin Cancer Res; 2024 May; 43(1):142. PubMed ID: 38745188
[TBL] [Abstract][Full Text] [Related]
60. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
